# Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

> **NCT01625429** · PHASE2 · UNKNOWN · sponsor: **Shanghai Cancer Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT01625429
- **Lead sponsor:** Shanghai Cancer Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2013-09
- **Final completion:** 2017-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2012-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625429, "Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01625429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*